Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Michael H. Davidson to Clinical Trials, Phase II as Topic

This is a "connection" page, showing publications Michael H. Davidson has written about Clinical Trials, Phase II as Topic.

 
Connection Strength
 
 
 
0.175
 
  1. Davidson MH. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol. 2013 May-Jun; 7(3 Suppl):S11-5.
    View in: PubMed
    Score: 0.116
  2. Nikolic D, Mikhailidis DP, Davidson MH, Rizzo M, Banach M. ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec; 237(2):705-10.
    View in: PubMed
    Score: 0.032
  3. Stalenhoef AF, Davidson MH, Robinson JG, Burgess T, Duttlinger-Maddux R, Kallend D, Goldberg AC, Bays H. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.